Analysts Offer Predictions for REGN FY2026 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will earn $26.24 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $695.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $9.55 earnings per share.

Several other brokerages also recently weighed in on REGN. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Bank of America dropped their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $7.40 during trading on Wednesday, reaching $529.24. 951,512 shares of the company traded hands, compared to its average volume of 879,349. The company's 50 day moving average is $563.19 and its two-hundred day moving average is $649.25. The firm has a market capitalization of $57.14 billion, a PE ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Capital International Investors boosted its position in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Norges Bank purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $802,036,000. GAMMA Investing LLC boosted its position in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Nuveen LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $343,764,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.